An interventional study of VR-CE in Alcohol Use Disorder, sponsored by Charite University, Berlin, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Alcoholism by Charite University, Berlin, Germany — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Charite University, Berlin, Germany.
Among the 14 studies in Alcoholism by Charite University, Berlin, Germany, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 14th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →4 of the 14 studies in Alcoholism by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18–70
Charite University, Berlin, Germany · Sites in Germany
Ages 16–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2
First in 2007; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 60 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 80 across the 7 interventional studies, 200 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
3 of the studies in Alcoholism by Charite University, Berlin, Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06308484Charite University, Berlin, GermanyNeuromodulation and Mindfulness Patients With AUD | 2027-06-30 |
| NCT06256952Charite University, Berlin, GermanyEffect of Social Isolation on the Role of Pavlovian Mechanisms for Control Over Alcohol Use | 2027-06-30 |
| NCT07667790Charite University, Berlin, GermanyEffects of Olfactory Stimuli in Virtual Reality Cue Exposure on Craving and Attentional Bias in Alcohol Use Disorder | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Alcoholism by Charite University, Berlin, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alcohol use disorder (AUD) is a prevalent and burdensome clinical condition with high relapse rates. A central risk factor for relapse is craving for alcohol-often accompanied by an attentional bias toward alcohol-related stimuli-which can be evoked by both real-world and virtual stimuli in immersive virtual reality (VR). In addition to visual and auditory stimuli, olfactory stimuli are increasingly recognized as important for creating realistic, multisensory VR environments. However, no systematic investigation has yet examined how olfactory stimuli embedded in VR-based cue exposure (VR-CE) influence craving and attentional bias in patients with AUD.
The goal of this prospective experimental single-arm clinical study, with a 2 (visual stimuli: neutral vs. alcohol-related VR scenarios) × 2 (olfactory stimuli: no odor vs. alcohol-related odor) within-subjects factorial design, is to determine how visual and olfactory stimuli contribute to the outcomes during a multimodal VR-CE in patients with AUD.
The main question is whether VR-CE with concurrent visual and olfactory alcohol-related stimuli induces a greater increase in craving and attentional bias from baseline than exposure to a single modality (visual or olfactory), as assessed by subjective and psychophysiological measures in patients with AUD.
Sixty patients with AUD, treated in inpatient or outpatient psychiatric clinics, will be enrolled in the study. Participants will receive written and verbal information about the study, and written informed consent for participation will be obtained. A screening for eligibility will then be conducted. This will include, among other things, a history of craving and the confirmation of normosmia. Sociodemographic data, questionnaires on craving, AUD characteristics, and tendency for immersion, as well as potentially confounding variables and factors influencing physiological parameters, will be collected. Participants will then be asked to name a beverage of their choice (beer, red wine, white wine, vodka, or schnaps), which will be presented to them visually and olfactorily during the VR-CE.
Before exposure to the VR scenarios, participants will be familiarized with the VR headset. Eye tracking within the head-mounted display (HMD) will be calibrated, and participants will be allowed to acclimatize to the VR environment. Subsequently, participants will be exposed to each of the four VR-CE conditions for 5 minutes (neutral visual+no odor; neutral visual+alcohol-related odor; alcohol-related visual+no odor; and alcohol-related visual+alcohol-related odor) in randomized order. Randomization will be implemented such that the visual stimuli are presented in blocks (i.e., both neutral or both alcohol-related VR scenarios), while the olfactory stimuli (no odor vs. alcohol-related odor) are randomized within each visual block. Prior to each visual block, participants will undergo a 5-minute VR baseline session in a black virtual room with blue orientation lines, which will serve as the baseline for subjective and psychophysiological parameters.
During exposure, psychophysiological parameters and eye-tracking data will be recorded, self-reported craving will be assessed three times and sense of presence once during each VR-CE condition. After the exposure, questionnaires to assess self-reported craving, attentional bias, sense of presence, affective reaction and cybersickness will be administered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The single-arm clinical study employs a 2 (visual: neutral vs. alcohol-related VR scenarios) × 2 (olfactory: no odor vs. alcohol-related odor) within-subjects factorial design. Each participant will complete all four conditions within the virtual reality cue exposure (VR-CE)
Device: VR-CE
Virtual reality cue exposure (VR-CE) using visual (neutral vs. alcohol-related VR scenarios) and olfactory (no odor vs. alcohol-related odor) stimuli conditions.
Self-reported craving (VAS-C)
Self-reported craving will be assessed using the visual analogue scale (VAS-C; range 0-10, higher score indicates higher levels of craving) during the 2 (visual) × 2 (olfactory) virtual reality cue exposure (VR-CE) conditions.
Time frame: Day 1, at minute 0:30, 2:30 and 4:30 during both VR baseline sessions and each VR-CE condition.
Psychophysiological craving index (heart rate variability, HRV)
For a multimodal craving measurement, heart rate variability (HRV) will be assessed as a psychophysiological craving index during both VR baseline sessions and each VR-CE condition.
Time frame: Day 1, continuously during both VR baseline sessions and each VR-CE condition.
Psychophysiological craving index (heart rate, HR)
For a multimodal craving measurement, heart rate (HR, in beats per minute (bpm)) will be assessed as a psychophysiological craving index during both VR baseline sessions and each VR-CE condition.
Time frame: Day 1, continuously during both VR baseline sessions and each VR-CE condition.
Psychophysiological craving index (electrodermal activity, EDA)
For a multimodal craving measurement, electrodermal activity (EDA, in microsiemens) will be assessed as a psychophysiological craving index during both VR baseline sessions and each VR-CE condition.
Time frame: Day 1, continuously during both VR baseline sessions and each VR-CE condition.
Psychophysiological craving index (respiratory rate, RR)
For a multimodal craving measurement, respiratory rate (RR) will be assessed as a psychophysiological craving index during both VR baseline sessions and each VR-CE condition.
Time frame: Day 1, continuously during both VR baseline sessions and each VR-CE condition.
Psychophysiological craving index (pupillometry)
For a multimodal craving measurement, pupillometry (pupil dilation in mm) will be assessed as a psychophysiological craving index during both VR baseline sessions and each VR-CE condition.
Time frame: Day 1, continuously during both VR baseline sessions and each VR-CE condition.
Self-reported craving (AUQ)
In addition to the VAS-C during VR baseline and VR-CE conditions, self-reported craving will be assessed using the Alcohol Urge Questionnaire (AUQ, range: 0-42, higher score indicates higher levels of craving).
Time frame: Day 1, after both VR baseline sessions and each VR-CE condition.
Self-reported attentional bias (AAS)
The Alcohol Attention Scale (AAS, item-range: 0-10, higher scores indicate higher levels of attention) will be used to assess self-reported attention toward the sight and smell of alcohol, as well as thoughts about drinking during each VR-CE condition with at least one alcohol-related stimulus.
Time frame: Day 1, after each VR-CE condition, except for the combination of neutral VR scenario and no odor.
Pupillometry indices of attentional bias
Pupillometry indices of attentional bias will be continuously assessed through gaze tracking via eye-tracking of alcohol-related and neutral stimuli during the alcohol-related VR scenario.
Time frame: Day 1, during the alcohol-related VR scenario.
Sense of presence (VAS-P)
Self-report of sense of presence will be assessed using a visual analogue scale (VAS-P; range 0-10, higher score indicates higher levels of sense of presence).
Time frame: Day one, during both VR baseline sessions and each VR-CE condition (minute 4:35).
Sense of presence (IPQ)
Self-report of sense of presence will be assessed after both VR baseline sessions and each VR-CE condition via the Igroup Presence Questionnaire (IPQ, range: 0-6, higher scores indicate higher sense of presence).
Time frame: Day 1, after both VR baseline sessions and each VR-CE condition.
Affective reaction (SAM)
Affective reaction will be assessed non-verbally using the three-item Self-Assessment Manikin (SAM, range: -4-4, higher scores indicate stronger affective reaction).
Time frame: Day 1, after both VR baseline sessions and each VR-CE condition.
Cybersickness (FMS)
Cybersickness during both VR baseline sessions and each VR-CE condition will be assessed using the Fast Motion Sickness Scale (FMS, range: 0-20, higher scores indicate higher cybersickness).
Time frame: Day 1, after both VR baseline sessions and each VR-CE condition.
Cybersickness (VRSQ)
In addition to the FMS, the Virtual Reality Sickness Questionnaire (VRSQ, range: 0-27, higher score indicates higher cybersickness) will be used to assess self-reported cybersickness.
Time frame: Day 1, after both VR baseline sessions and each VR-CE condition.
Sociodemographic variables
Sociodemographic variables will be assessed, e.g. age, gender, sex
Time frame: Day one, before VR-CE
AUD characteristics (AUDIT)
Alcohol use disorder (AUD) characteristics, such as AUD screening score (AUDIT, range: 0-40, higher score indicates greater likelihood of alcohol dependence) will be assessed.
Time frame: Day 1, before the VR-CE
AUD characteristics (ADS)
Alcohol use disorder (AUD) characteristics, such as addiction severity (Alcohol Dependence Scale, ADS, range: 1-47, higher score indicates greater alcohol dependance severity) will be assessed.
Time frame: Day 1, before the VR-CE
Self-reported trait craving before VR-CE (OCDS)
Self-reported trait craving prior to VR-CE will be assessed using the Obsessive Compulsive Drinking Scale (OCDS, range: 0-40, higher scores indicate higher craving).
Time frame: Day 1, before VR-CE
Self-reported trait craving before VR-CE (CAS-A)
Self-reported trait craving prior to VR-CE will be assessed using the Craving Automated Scale for Alcohol (CAS-A, range: 0-75, higher scores indicate higher craving).
Time frame: Day 1, before VR-CE
Immersive tendencies (ITQ)
Participants ability to feel immersed or "present" in an environment will be assessed as a trait using the Immersive Tendencies Questionnaire (ITQ, range: 18-126, higher scores indicate higher immersive tendencies).
Time frame: Day 1, before VR-CE
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 8 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →